Logo image of STRO

SUTRO BIOPHARMA INC (STRO) Stock Fundamental Analysis

NASDAQ:STRO - Nasdaq - US8693671021 - Common Stock - Currency: USD

1.77  -0.06 (-3.28%)

After market: 1.8 +0.03 (+1.69%)

Fundamental Rating

3

Overall STRO gets a fundamental rating of 3 out of 10. We evaluated STRO against 571 industry peers in the Biotechnology industry. The financial health of STRO is average, but there are quite some concerns on its profitability. STRO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year STRO has reported negative net income.
STRO had a negative operating cash flow in the past year.
In the past 5 years STRO always reported negative net income.
STRO had negative operating cash flow in 4 of the past 5 years.
STRO Yearly Net Income VS EBIT VS OCF VS FCFSTRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M

1.2 Ratios

With a decent Return On Assets value of -27.43%, STRO is doing good in the industry, outperforming 71.94% of the companies in the same industry.
STRO has a Return On Equity of -111.45%. This is comparable to the rest of the industry: STRO outperforms 42.63% of its industry peers.
Industry RankSector Rank
ROA -27.43%
ROE -111.45%
ROIC N/A
ROA(3y)-27.63%
ROA(5y)-25.34%
ROE(3y)-56.02%
ROE(5y)-46.95%
ROIC(3y)N/A
ROIC(5y)N/A
STRO Yearly ROA, ROE, ROICSTRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 200 300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for STRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STRO Yearly Profit, Operating, Gross MarginsSTRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

More info and screens

6

2. Health

2.1 Basic Checks

STRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for STRO has been increased compared to 1 year ago.
STRO has more shares outstanding than it did 5 years ago.
STRO has a better debt/assets ratio than last year.
STRO Yearly Shares OutstandingSTRO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
STRO Yearly Total Debt VS Total AssetsSTRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -1.82, we must say that STRO is in the distress zone and has some risk of bankruptcy.
STRO has a Altman-Z score (-1.82) which is comparable to the rest of the industry.
There is no outstanding debt for STRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.82
ROIC/WACCN/A
WACC9.72%
STRO Yearly LT Debt VS Equity VS FCFSTRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 3.09 indicates that STRO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.09, STRO is doing worse than 63.94% of the companies in the same industry.
STRO has a Quick Ratio of 3.09. This indicates that STRO is financially healthy and has no problem in meeting its short term obligations.
STRO has a worse Quick ratio (3.09) than 61.99% of its industry peers.
Industry RankSector Rank
Current Ratio 3.09
Quick Ratio 3.09
STRO Yearly Current Assets VS Current LiabilitesSTRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

STRO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.97%, which is quite impressive.
Looking at the last year, STRO shows a very strong growth in Revenue. The Revenue has grown by 230.98%.
STRO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.96% yearly.
EPS 1Y (TTM)45.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.16%
Revenue 1Y (TTM)230.98%
Revenue growth 3Y53.24%
Revenue growth 5Y31.96%
Sales Q2Q%-49.66%

3.2 Future

Based on estimates for the next years, STRO will show a decrease in Earnings Per Share. The EPS will decrease by -3.57% on average per year.
Based on estimates for the next years, STRO will show a very strong growth in Revenue. The Revenue will grow by 35.55% on average per year.
EPS Next Y-66.09%
EPS Next 2Y-31.98%
EPS Next 3Y-18.08%
EPS Next 5Y-3.57%
Revenue Next Year13.89%
Revenue Next 2Y2.17%
Revenue Next 3Y-0.91%
Revenue Next 5Y35.55%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
STRO Yearly Revenue VS EstimatesSTRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
STRO Yearly EPS VS EstimatesSTRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

STRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STRO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STRO Price Earnings VS Forward Price EarningsSTRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STRO Per share dataSTRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A cheap valuation may be justified as STRO's earnings are expected to decrease with -18.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.98%
EPS Next 3Y-18.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for STRO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SUTRO BIOPHARMA INC

NASDAQ:STRO (2/21/2025, 8:00:01 PM)

After market: 1.8 +0.03 (+1.69%)

1.77

-0.06 (-3.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)03-24 2025-03-24/amc
Inst Owners78.33%
Inst Owner Change-98.65%
Ins Owners0.82%
Ins Owner Change0.55%
Market Cap145.95M
Analysts84.71
Price Target11.73 (562.71%)
Short Float %4.98%
Short Ratio3.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.12%
Min EPS beat(2)21.27%
Max EPS beat(2)26.97%
EPS beat(4)3
Avg EPS beat(4)52.29%
Min EPS beat(4)-1.02%
Max EPS beat(4)161.92%
EPS beat(8)4
Avg EPS beat(8)25.7%
EPS beat(12)5
Avg EPS beat(12)17.73%
EPS beat(16)6
Avg EPS beat(16)7.45%
Revenue beat(2)1
Avg Revenue beat(2)-12.67%
Min Revenue beat(2)-45.24%
Max Revenue beat(2)19.89%
Revenue beat(4)3
Avg Revenue beat(4)206.13%
Min Revenue beat(4)-45.24%
Max Revenue beat(4)844.21%
Revenue beat(8)5
Avg Revenue beat(8)100.42%
Revenue beat(12)7
Avg Revenue beat(12)76.35%
Revenue beat(16)9
Avg Revenue beat(16)72.05%
PT rev (1m)0%
PT rev (3m)-4.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.02%
EPS NY rev (1m)0%
EPS NY rev (3m)1.92%
Revenue NQ rev (1m)-0.24%
Revenue NQ rev (3m)11.57%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.91
P/FCF N/A
P/OCF N/A
P/B 1.31
P/tB 1.31
EV/EBITDA N/A
EPS(TTM)-1.61
EYN/A
EPS(NY)-3.1
Fwd EYN/A
FCF(TTM)-1.32
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS1.95
BVpS1.35
TBVpS1.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.43%
ROE -111.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.63%
ROA(5y)-25.34%
ROE(3y)-56.02%
ROE(5y)-46.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 49.11%
Cap/Sales 2.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.09
Quick Ratio 3.09
Altman-Z -1.82
F-Score5
WACC9.72%
ROIC/WACCN/A
Cap/Depr(3y)172.66%
Cap/Depr(5y)151.32%
Cap/Sales(3y)13.05%
Cap/Sales(5y)12.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.16%
EPS Next Y-66.09%
EPS Next 2Y-31.98%
EPS Next 3Y-18.08%
EPS Next 5Y-3.57%
Revenue 1Y (TTM)230.98%
Revenue growth 3Y53.24%
Revenue growth 5Y31.96%
Sales Q2Q%-49.66%
Revenue Next Year13.89%
Revenue Next 2Y2.17%
Revenue Next 3Y-0.91%
Revenue Next 5Y35.55%
EBIT growth 1Y28.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.72%
EBIT Next 3Y-23.96%
EBIT Next 5YN/A
FCF growth 1Y-9076.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1913.52%
OCF growth 3YN/A
OCF growth 5YN/A